06 Nov 2025: DDi (Drug Development informatics), a leader in regulatory, clinical, and enterprise technology solutions, has been honored with the prestigious Global 100 – 2026 Business Excellence award by GPMG. This recognition highlights DDi’s strong commitment to innovation, quality delivery, and transformative impact across the global life sciences ecosystem.

The award acknowledges DDi’s advancements in intelligent automation, data harmonization, and AI-driven platforms that simplify regulatory and clinical workflows for pharmaceutical and medical device organizations. Products like Visu, Vistaar, mIRT, smartDOC and solutions like eIFU and Regulatory Intelligence capabilities have helped life science companies improve operational efficiency, accelerate submissions, and enhance compliance transparency.

Receiving the Global 100 distinction reinforces DDi’s position as a trusted technology partner, continuously driving smarter and more connected regulatory processes worldwide.

06 Nov 2025: A major global medical device company has chosen DDi’s Visu platform to strengthen and streamline its Unique Device Identification (UDI) compliance processes across international markets as well as EUDAMED.

The selection comes as regulatory compliance expectations for device traceability continue to expand across regions, requiring manufacturers to maintain accurate product data, ensure timely submissions, and manage ongoing updates across multiple health authority systems.

Visu, DDi’s regulatory and quality data management and operations platform, centralizes UDI data, automates validation checks, and simplifies submissions to global databases including the FDA GUDID and EU EUDAMED.

06 Nov 2025: A leading $2 Billion UK-headquartered medical device manufacturer valued has selected DDi’s AI powered Reg Intel platform to enhance its global regulatory intelligence and compliance operations. The adoption reflects increasing industry focus on automated, real-time regulatory process management as companies navigate evolving global requirements across the U.S., EU, UK, and emerging markets

DDi’s Reg Intel platform provides continuous regulatory updates, structured intelligence, and proactive change alerts, enabling regulatory and quality teams to respond quickly and reduce manual monitoring efforts. Its built-in AI capabilities help harmonize regulatory information, streamline assessment workflows, and support faster submission readiness.

After a detailed evaluation, the company chose DDi’s Reg Intel platform for its depth of coverage, data accuracy, AI based workflows, and seamless integration with internal systems. The implementation is expected to improve compliance preparedness, accelerate market access efforts, and strengthen audit readiness.

DDi, a leading provider of technology solutions for the life sciences industry, has announced a major enhancement to its Visu platform, integrating advanced artificial intelligence to revolutionize project management for regulatory teams in the medical device, pharmaceutical, and biotech companies.

The newly enhanced AI-based Regulatory Project Management feature brings automation, predictive analytics, and intelligent decision support to regulatory project teams, enabling faster timelines, improved collaboration, and proactive risk identification. With the increasing complexity of product development in life sciences, these capabilities are designed to streamline project execution from early-stage planning through to commercialization.

Visu’s AI enhancements provide regulatory teams with actionable insights through real-time dashboards, regulatory forecasting, collaboration with cross-functional teams, resource optimization, and adaptive learning models. The platform is tailored to meet the specific demands of both Medical Device Project Management and Pharma & Biotech Project Management, ensuring regulatory alignment and operational transparency.

“We’re committed to empowering life sciences organizations with intelligent tools that adapt to the dynamic nature of their projects,” said Mahesh Malneedi, CTO at DDi. “By infusing AI into Visu, we’re delivering a new level of control, speed, and foresight to our clients’ project management processes.”

DDi, a global leader in regulatory and clinical development solutions for the life sciences industry, has been honored with the prestigious ‘Best Global Regulatory & Clinical Development Partner 2025’ award by Global Health & Pharma (GHP). This recognition marks a significant milestone in DDi’s commitment to driving innovation and excellence across regulatory, clinical, and technology-driven services.

Presented as part of GHP’s annual International Life Sciences Awards, this accolade celebrates DDi’s exceptional performance, client-centric approach, and continued impact on advancing healthcare solutions worldwide. The award underscores DDi’s strengths in delivering efficient, compliant, and technology-enabled services that accelerate drug development and regulatory approvals.